Organization & Developments: Spectrum Pharma

Parents

2011: Cancer Drug Shortage Shines Light On Spectrum Pharmaceuticals' (SPPI) Forgotten Treatments (2011)
2011: Spectrum completed Fusilev's clinical trials and in 2008 it was approved to treat osteosarcoma, a type of bone cancer.
2016: Ligand Pharma Adds Tech, Grows On Partners’ Success
2017: Spectrum Pharmaceuticals: Buy The Dip - Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
2018: Spectrum Pharmaceuticals: Continued Upside In 2018 - Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
2019: Spectrum Suffers BLA Setback, But Based On Deadline, It Was For The Better_seekingalpha.com
2020: Spectrum Pharma Is Down But Not Out
2021: Sizing Up Spectrum Pharmaceuticals
2022: Spectrum Pharmaceuticals: Some Last Words
2022: Spectrum to lay off R&D staff after FDA drug rejection
Its major revenue generator, Fusilev, was acquired in 2006 when it bought the oncology line of Targent.
Spectrum doesn't do drug discovery of its own, but looks for opportunities to salvage others research.